Adicet Bio 执行1至16次逆向股票拆分 12月30日 以满足Nasdaq的出价规则 Adicet Bio to execute 1-to-16 reverse stock split Dec. 30 to meet Nasdaq’s bid price rule.

Adicet Bio(ACET)正从2025年12月30日起实施1至16次逆向股票分割,以帮助满足Nasdaq的最低投标价格要求。 Adicet Bio (ACET) is implementing a 1-to-16 reverse stock split effective December 30, 2025, to help meet Nasdaq’s minimum bid price requirement. 这一转移将未清股份从1.533亿减少到约960万,没有发行分股股票。 The move reduces outstanding shares from 153.3 million to about 9.6 million, with no fractional shares issued. 在宣布之后,该股票在12月26日收盘时跌幅为0.49美元,下跌5.78%. The stock closed at $0.49 on December 26, down 5.78%, following the announcement. 该公司开发现成的伽马-德尔塔细胞疗法,报告每季度每股损失2.29美元,狼疮试验回复率为100%,这可能有助于今后的第二阶段开发。 The company, developing off-the-shelf gamma delta T cell therapies, reported a quarterly loss of $0.29 per share and a 100% response rate in a lupus trial, which may support future Phase 2 development. 机构投资者持有83.89%的股份,分析师维持“机动购买”评级,目标值为7.33美元。 Institutional investors hold 83.89% of shares, and analysts maintain a "Moderate Buy" rating with a $7.33 target.